Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kybella Approval Shows How To Work With FDA On Clinical Outcome Assessments

Executive Summary

Kythera met FDA's strict evidentiary requirements for clinician- and patient-reported outcomes assessments through close and frequent interactions with the agency and by addressing regulatory concerns about the instruments' design, validation and use in Phase III trials for the submental fat treatment.

Advertisement

Related Content

Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition
Behind The Approval Letter: Drug Review Profiles
Chin Fat Not A 'Serious Condition' Worthy Of Priority Review, FDA Says
Chin Fat Not A 'Serious Condition' Worthy Of Priority Review, FDA Says
Patient-Reported Outcomes Data Earned Kybella A Claim For Emotional Impacts
Kythera Claims Kybella Name After Lundbeck Stumbles With Carbella
Kybella Reviewers
Patient-Reported Outcomes To Be Available For ‘One-Stop Shopping’ In FDA Compendium
FDA's Final PRO Guidance Grounds Policy With More Details

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel